Abcam, ab99889, Anti-MSH6 antibody [SP93]

Size: 100µL / 500µL / 1mL
Anti-MSH6 antibody [SP93] (ab99889) is a rabbit monoclonal antibody detecting MSH6 in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IHC-P, ICC/IF . Suitable for Human, Mouse . - KO validated for confirmed specificity - Biophysical QC for unrivalled batch-batch consistency - Trusted since 2010
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:SP93,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Human,
Applications:WB, Flow Cyt (Intra), ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Epitope:Internal region

Product details:
What is this antibody validated in?
Anti-MSH6 antibody [SP93] (ab99889) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Flow Cytometry (Flow Cyt), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse samples.
Collaboration
Anti-MSH6 [SP93] (ab99889) is a clone from the portfolio of Spring Bioscience (Roche) SP clones which have been optimised for immunohistochemistry (IHC).
Specificity confirmed
The specificity of Anti-MSH6 antibody [SP93] (ab99889) has been confirmed by Western blot testing in MSH6 Knockout HAP1 cells.
Other related products
We have a range of other formats of antibody clone [SP93] also available for your convenience: ab99889, Carrier free -
ab238805
, ab279563
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A/G, Purification notes-Purified from TCS by protein A/G., Storage buffer-pH: 7.6Preservative: 0.1% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
MSH6 also known as MutS Homolog 6 is a DNA repair protein that plays a role in the mismatch repair (MMR) system. It has a molecular mass of approximately 136 kDa. MSH6 forms a heterodimer with MSH2 called MutSα and this complex identifies base-pair mismatches and insertion-deletion loops during DNA replication. It is expressed in various tissues throughout the body and high levels are often found in proliferative tissues where active DNA replication occurs.
Biological function summary
MSH6 functions as part of the MMR complex which is essential for maintaining genomic stability. The MutSα complex where MSH6 pairs with MSH2 operates along with other proteins in the MMR pathway to correct DNA replication errors. MSH6 is also known to interact with PCNA a DNA polymerase processivity factor which facilitates its role in the repair process.
Pathways
MSH6 participates prominently in the DNA mismatch repair pathway. This pathway is critical for correcting DNA errors and preventing mutations during replication. In association with MLH1-PMS2 (MutLα complex) MSH6 ensures that DNA integrity is preserved. Additionally MSH6 is involved in the base excision repair (BER) pathway where it collaborates with other repair proteins to fix small base lesions.
MSH6 has a significant connection with Lynch syndrome also known as hereditary nonpolyposis colorectal cancer (HNPCC). This condition is characterized by germline mutations in MMR genes including MSH6 leading to increased cancer risk particularly in the colon. Moreover alterations in MSH6 can contribute to microsatellite instability a feature seen in certain types of endometrial cancer. Mutations in MSH2 often accompany MSH6 mutations in these disorders further impacting the MMR pathway's efficiency.